ADB-P7AICA

ADB-P7AICA is a synthetic cannabinoid that has been used in scientific research. It is a potent and selective agonist for the CB1 receptor, with a Ki of 0.21 nM, making it roughly 25x more potent than THC.

Chemistry

ADB-P7AICA is a derivative of ADBICA, which itself is a derivative of ABICA. The chemical structure of ADB-P7AICA includes a pentyl chain attached to the nitrogen of the indazole group, and a 7-hydroxyisopropyl group attached to the 3-position of the indazole.

Pharmacology

As a potent and selective agonist for the CB1 receptor, ADB-P7AICA has similar effects to other cannabinoids. However, due to its potency, it may have a higher risk of causing cannabinoid hyperemesis syndrome or other adverse effects. The exact mechanism of action of ADB-P7AICA is not fully understood, but it is believed to work by mimicking the effects of naturally occurring endocannabinoids in the body.

Legal Status

The legal status of ADB-P7AICA varies by country. In some countries, it is classified as a controlled substance due to its similarity to other synthetic cannabinoids. In others, it is legal for research purposes but not for human consumption.

See Also

• Synthetic cannabinoids
• Cannabinoid receptor
• Cannabinoid hyperemesis syndrome

References

‎